SCHEMBL30989884

SCHEMBL30989884

COc1ncc(F)cc1C(=O)N(C)Cc1ccccc1C#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ GAA P10253 1/20 0.39
▸ NLRP3 Q96P20 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ GPR6 P46095 1/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ TSHR P16473 1/20 0.37
▸ TACR1 P25103 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ GPBAR1 Q8TDU6 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ SGMS2 Q8NHU3 1/20 0.36
▸ JAK1 P23458 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989882 0.86 MEN1 (0.48) NPC1RAB9AGAANLRP3MEN1
SCHEMBL30989781 0.82 RIPK1 (0.46) NPC1GAANLRP3MEN1KMT2A
SCHEMBL30989869 0.81 LRRK2 (0.37) GAAGPR6GPBAR1
SCHEMBL30989880 0.81 LRRK2 (0.37) GAAGPR6GPBAR1
SCHEMBL30989856 0.81 GPR6 (0.40) NPC1RAB9AGAANLRP3GPR6
SCHEMBL30989911 0.80 RIPK1 (0.46) GAAGPR6ALDH1A1GRIN1GRIN2B
SCHEMBL30989936 0.79 RIPK1 (0.47) NPC1GAAMEN1KMT2AGPR6
SCHEMBL30989827 0.78 PIK3C3 (0.41) NPC1GAAMEN1KMT2AGPR6
SCHEMBL30989864 0.77 CLK1 (0.51) GAAMEN1KMT2AALDH1A1
SCHEMBL30989737 0.72 PIK3C3 (0.37) GPR6GPBAR1JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback